Novartis reported promising initial results from a 9-month interim assessment of the Phase III APPLAUSE-IgAN trial. The experimental factor B inhibitor, iptacopan, showed superior effectiveness in reducing proteinuria compared to placebo.
This article summarized the latest R&D progress of brimonidine tartrate/timolol maleate, the Mechanism of Action for brimonidine tartrate/timolol maleate, and the drug target R&D trends for brimonidine tartrate/timolol maleate.
JCR Pharmaceuticals Co., Ltd. has disclosed critical findings from the midway 52-week data of its global research phase I/II involving JR-171 (lepunafusp alfa) in patients diagnosed with mucopolysaccharidosis type I.
In the rapidly escalating field of biological research, the importance of intellectual property (IP) has never been more critical. With biological sequences becoming paramount in the biotech and pharmaceutical sectors, the advent of a convenient, comprehensive patent search database is indeed a significant breakthrough.